Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients

Detalhes bibliográficos
Autor(a) principal: Condinho, Mónica
Data de Publicação: 2016
Outros Autores: Sá, Jorge, Eliseu, Arquimínio, Figueiredo, Isabel Vitória, Sinogas, Carlos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25756/rpf.v8i3.123
Resumo: Introduction: The positive impact of pharmacist-physician collaborative care has been reported in the international literature, although examples of this impact are limited in Portugal. We aim to underline the clinical added value for hypertensive patients that results from pharmacist-physician collaborations.Methods: A community trial was conducted at a Portuguese family health unit for 19 months. The intervention group was randomly selected from the global records and members of the group received pharmaceutical care in addition to physician care. The comparison group received only physician care. Both groups were comparable at the beginning of the study. In the intervention group, we analysed the hypertensive patients to evaluate the impact of pharmacist-physician collaboration on the patients’ blood pressure levels. This evaluation was performed by comparing the obtained blood pressure levels with the levels at baseline and between the groups.Results: A total of 17 patients with hypertension were enrolled in the pharmaceutical care programme, 12 of whom were female. The mean age was 68.50±3.26 years and, on average, each patient consumed 6.06±0.93 medicinal products. Thirteen patients were uncontrolled. Compared with the baseline, the intervention group achieved mean reductions of 28.85±5.90 mmHg (p < 0.0005) and 11.23±2.75 mmHg (p < 0.005) in their systolic and diastolic blood pressure, respectively. Considering the comparison group, improvements of 18.63±6.44 mmHg (p = 0.011) in systolic blood pressure and 9.03±2.63 mmHg ( p < 0.005) in diastolic blood pressure were observed.Conclusion: Pharmacist-physician collaborative care adds clinical value to the typical physician care provided to hypertensive patients within the context of a Portuguese family health unit. 
id RCAP_08a8ddd3245042b91f4e6da036aaa194
oai_identifier_str oai:ojs.farmacoterapia.pt:article/123
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive PatientsImpacto Clínico de um Programa de Acompanhamento Farmacoterapêutico Implementado numa Unidade de Saúde Familiar: Resultados de uma Colaboração entre Farmacêutico e Médico no Tratamento de Doentes HipertensosIntroduction: The positive impact of pharmacist-physician collaborative care has been reported in the international literature, although examples of this impact are limited in Portugal. We aim to underline the clinical added value for hypertensive patients that results from pharmacist-physician collaborations.Methods: A community trial was conducted at a Portuguese family health unit for 19 months. The intervention group was randomly selected from the global records and members of the group received pharmaceutical care in addition to physician care. The comparison group received only physician care. Both groups were comparable at the beginning of the study. In the intervention group, we analysed the hypertensive patients to evaluate the impact of pharmacist-physician collaboration on the patients’ blood pressure levels. This evaluation was performed by comparing the obtained blood pressure levels with the levels at baseline and between the groups.Results: A total of 17 patients with hypertension were enrolled in the pharmaceutical care programme, 12 of whom were female. The mean age was 68.50±3.26 years and, on average, each patient consumed 6.06±0.93 medicinal products. Thirteen patients were uncontrolled. Compared with the baseline, the intervention group achieved mean reductions of 28.85±5.90 mmHg (p < 0.0005) and 11.23±2.75 mmHg (p < 0.005) in their systolic and diastolic blood pressure, respectively. Considering the comparison group, improvements of 18.63±6.44 mmHg (p = 0.011) in systolic blood pressure and 9.03±2.63 mmHg ( p < 0.005) in diastolic blood pressure were observed.Conclusion: Pharmacist-physician collaborative care adds clinical value to the typical physician care provided to hypertensive patients within the context of a Portuguese family health unit. Introdução: O impacto positivo da colaboração entre farmacêutico-médico para a saúde do doente está bem documentado na literatura internacional. Em Portugal, os exemplos de colaboração são limitados. Com este trabalho pretendemos sublinhar a mais-valia clínica da colaboração farmacêutico-médico em doentes hipertensos.Métodos: Ensaio comunitário desenvolvido numa unidade de saúde familiar portuguesa, durante 19 meses. O grupo de intervenção, selecionado aleatoriamente do ficheiro global, foi submetido a acompanhamento farmacoterapêutico pelo farmacêutico. O grupo de comparação recebeu apenas os cuidados médicos habituais. Ambos os grupos eram comparáveis à partida. Analisámos os doentes hipertensos para avaliar o impacto da colaboração farmacêutico-médico nos níveis de pressão arterial. A avaliação foi efetuada por comparação com o ponto de partida e entre os dois grupos.Resultados: Integraram o programa de acompanhamento farmacoterapêutico, 17 hipertensos, 12 do género feminino com idade média de 68,50±3,26 e um consumo médio de medicamentos de 6,06±0,93. Do total, 13 não estavam controlados. Comparando com o início, o grupo de intervenção reduziu, em média, 28,85±5,90 mmHg (p < 0,0005) na pressão arterial sistólica e 11,23±2,75 mmHg (p < 0,005) na diastólica. Na comparação entre grupos, registou-se uma redução de 18,63±6,44 mmHg (p = 0,011) na pressão arterial sistólica e de 9,03±2,63 mmHg (p < 0,005) na diastólica.Conclusão: A colaboração farmacêutico-médico em doentes hipertensos numa unidade de saúde familiar Portuguesa acrescentou mais-valia clínica aos cuidados de saúde habitualmente recebidos pelos doentes.Formifarma2016-09-14info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v8i3.123https://doi.org/10.25756/rpf.v8i3.123Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 8 No 3 (2016): July; 7-14Revista Portuguesa de Farmacoterapia; v. 8 n. 3 (2016): Julho; 7-142183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://revista.farmacoterapia.pt/index.php/rpf/article/view/123http://revista.farmacoterapia.pt/index.php/rpf/article/view/123/101Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessCondinho, MónicaSá, JorgeEliseu, ArquimínioFigueiredo, Isabel VitóriaSinogas, Carlos2023-09-01T04:33:37Zoai:ojs.farmacoterapia.pt:article/123Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:35.014967Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
Impacto Clínico de um Programa de Acompanhamento Farmacoterapêutico Implementado numa Unidade de Saúde Familiar: Resultados de uma Colaboração entre Farmacêutico e Médico no Tratamento de Doentes Hipertensos
title Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
spellingShingle Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
Condinho, Mónica
title_short Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
title_full Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
title_fullStr Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
title_full_unstemmed Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
title_sort Clinical Impact of a Pharmaceutical Care Programme Developed in a Family Health Unit: Results of a Pharmacist-Physician Collaboration in the Treatment of Hypertensive Patients
author Condinho, Mónica
author_facet Condinho, Mónica
Sá, Jorge
Eliseu, Arquimínio
Figueiredo, Isabel Vitória
Sinogas, Carlos
author_role author
author2 Sá, Jorge
Eliseu, Arquimínio
Figueiredo, Isabel Vitória
Sinogas, Carlos
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Condinho, Mónica
Sá, Jorge
Eliseu, Arquimínio
Figueiredo, Isabel Vitória
Sinogas, Carlos
description Introduction: The positive impact of pharmacist-physician collaborative care has been reported in the international literature, although examples of this impact are limited in Portugal. We aim to underline the clinical added value for hypertensive patients that results from pharmacist-physician collaborations.Methods: A community trial was conducted at a Portuguese family health unit for 19 months. The intervention group was randomly selected from the global records and members of the group received pharmaceutical care in addition to physician care. The comparison group received only physician care. Both groups were comparable at the beginning of the study. In the intervention group, we analysed the hypertensive patients to evaluate the impact of pharmacist-physician collaboration on the patients’ blood pressure levels. This evaluation was performed by comparing the obtained blood pressure levels with the levels at baseline and between the groups.Results: A total of 17 patients with hypertension were enrolled in the pharmaceutical care programme, 12 of whom were female. The mean age was 68.50±3.26 years and, on average, each patient consumed 6.06±0.93 medicinal products. Thirteen patients were uncontrolled. Compared with the baseline, the intervention group achieved mean reductions of 28.85±5.90 mmHg (p < 0.0005) and 11.23±2.75 mmHg (p < 0.005) in their systolic and diastolic blood pressure, respectively. Considering the comparison group, improvements of 18.63±6.44 mmHg (p = 0.011) in systolic blood pressure and 9.03±2.63 mmHg ( p < 0.005) in diastolic blood pressure were observed.Conclusion: Pharmacist-physician collaborative care adds clinical value to the typical physician care provided to hypertensive patients within the context of a Portuguese family health unit. 
publishDate 2016
dc.date.none.fl_str_mv 2016-09-14
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25756/rpf.v8i3.123
https://doi.org/10.25756/rpf.v8i3.123
url https://doi.org/10.25756/rpf.v8i3.123
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://revista.farmacoterapia.pt/index.php/rpf/article/view/123
http://revista.farmacoterapia.pt/index.php/rpf/article/view/123/101
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia
http://creativecommons.org/licenses/by-nc-nd/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia
http://creativecommons.org/licenses/by-nc-nd/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Formifarma
publisher.none.fl_str_mv Formifarma
dc.source.none.fl_str_mv Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 8 No 3 (2016): July; 7-14
Revista Portuguesa de Farmacoterapia; v. 8 n. 3 (2016): Julho; 7-14
2183-7341
1647-354X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799129986199715840